A CXCR2-selective antagonist (SB225002) abolishes the protection conferred by PLD2 deficiency during experimental sepsis, suggesting that enhanced CXCR2 expression in neutrophils promotes survival in PLD2−/− mice [18]. This evidence concerns the gene CXCR2 and Sepsis.